Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Rapid CommunicationShort Communication

Elimination Pathways of [14C]Losoxantrone in Four Cancer Patients

Amita S. Joshi, Henry J. Pieniaszek Jr., Everett E. Vokes, Nicholas J. Vogelzang, Anna F. Davidson, Lauren E. Richards, Min F. Chai, Michael Finizio and Mark J. Ratain
Drug Metabolism and Disposition February 2001, 29 (2) 96-99;
Amita S. Joshi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry J. Pieniaszek Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Everett E. Vokes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas J. Vogelzang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna F. Davidson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren E. Richards
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min F. Chai
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Finizio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. Ratain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Losoxantrone is an anthrapyrazole derivative in Phase III development in the U.S. for solid tumors, notably breast cancer. To obtain information on the routes of elimination of the drug, a study was conducted in four patients with advanced solid tumors, which involved intravenous administration of 100 μCi of [14C]losoxantrone for a total dose of 50 mg/m2 during the first course of losoxantrone therapy. Blood, urine, and feces were collected for up to 2 weeks and were analyzed for total radioactivity and parent drug. In addition, feces were profiled for the presence of metabolites. Plasma concentrations of total radioactivity exhibited a temporal pattern similar to the parent drug. Combined recovery of administered total radioactivity from urine and feces was 70% with the majority (87%) of this radioactivity excreted in the feces, presumably via biliary excretion. Feces extracts were profiled for metabolites using a high-performance liquid chromatography method developed to separate synthetic standards of previously identified human urinary metabolites. Only intact losoxantrone was found in the feces. About 9% of the dose was excreted in the urine, primarily during the first 24 h and mostly in the form of parent compound. Collectively, these data indicate that fecal excretion of unmetabolized drug via biliary and/or intestinal excretion is the primary pathway of intravenously administered losoxantrone elimination in cancer patients with refractory solid tumors.

Footnotes

  • Send reprint requests to: Amita S. Joshi, Ph.D., Genentech, Inc., 1 DNA Way, MS-70, South San Francisco, CA 94080. E-mail: amita{at}gene.com

  • This work was presented in abstract form at the Annual Conference of the American College of Clinical Pharmacology and published as an abstract in the College's Journal [J Clin Pharmacol37:868 (1997)].

  • Abbreviations used are::
    LSC
    liquid scintillation counting
    HPLC
    high-performance liquid chromatography
    UV/Vis
    UV/visible
    • Received August 25, 2000.
    • Accepted October 30, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 29 (2)
Drug Metabolism and Disposition
Vol. 29, Issue 2
1 Feb 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Elimination Pathways of [14C]Losoxantrone in Four Cancer Patients
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Rapid CommunicationShort Communication

Elimination Pathways of [14C]Losoxantrone in Four Cancer Patients

Amita S. Joshi, Henry J. Pieniaszek, Everett E. Vokes, Nicholas J. Vogelzang, Anna F. Davidson, Lauren E. Richards, Min F. Chai, Michael Finizio and Mark J. Ratain
Drug Metabolism and Disposition February 1, 2001, 29 (2) 96-99;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Rapid CommunicationShort Communication

Elimination Pathways of [14C]Losoxantrone in Four Cancer Patients

Amita S. Joshi, Henry J. Pieniaszek, Everett E. Vokes, Nicholas J. Vogelzang, Anna F. Davidson, Lauren E. Richards, Min F. Chai, Michael Finizio and Mark J. Ratain
Drug Metabolism and Disposition February 1, 2001, 29 (2) 96-99;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Preincubation Effects on Inhibition of OCT1 by CsA
  • Carbamazepine Metabolite and Hypersensitivity Reactions
  • SULT4A1 Preserves Mitochondrial Function
Show more Short Communication

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics